English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Hugo Arasanz‡ ,1,2, Miren Zuazo‡ ,1, Ruth Vera*,2, Grazyna Kochan**,1 & David Escors***,1,3 1Immunomodulation Group, Navarrabiomed-Fundación Miguel Servet, IdISNA, Complejo Hospitalario de Navarra (CHN), Irunlarrea 3, 31008 Pamplona, Navarra, Spain 2Department of Oncology, Complejo Hospitalario de Navarra (CHN), Irunlarrea 3, 31008 Pamplona, Navarra, Spain 3Division of Infection & Immunity, Rayne Institute, University College London, 5 University Street, London WC1E 6JF, UK *Author for correspondence: ruth.vera.garcia@navarra.es **Author for correspondence: grazyna.kochan@navarra.es ***Author for correspondence: descorsm@navarra.es ‡Authors contributed equally

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies